New Partnership in AI-Driven Digital Pathology
Lunit, a pioneering provider of artificial intelligence solutions for cancer diagnostics and precision oncology, is excited to announce a strategic partnership with Labcorp, a global leader in laboratory services. This collaboration aims to push the boundaries of innovation in digital pathology and artificial intelligence applications, specifically targeted at oncology research and clinical care.
Transforming Cancer Diagnostics
The primary goal of this partnership is to combine Labcorp's extensive experience in clinical and pathology practices with Lunit's advanced AI algorithms. Together, they aim to reshape the analysis and interpretation of tumor microenvironments fundamentally. By merging high-resolution whole-slide imaging with AI-powered spatial profiling, this collaboration aspires to unlock new insights that can facilitate biomarker discovery and refine precision immuno-oncology strategies.
Initial Results Presented at Major Conferences
The first set of results from this collaboration was recently highlighted at significant scientific gatherings. Notable among these were:
- Society for Immunotherapy of Cancer (SITC): At this conference, the team demonstrated how AI-based spatial profiling can identify immune-active subtypes of non-small cell lung cancer (NSCLC) tumors possessing the MET exon 14 skipping mutation, which correlates with enhanced outcomes in immunotherapy. The research, utilizing Lunit SCOPE IO, analyzed over 370 pathology slides to delineate immune phenotypes related to various MET alterations, including exon 14 skipping and amplification.
- Association for Molecular Pathology (AMP): This study revealed distinct tumor-immune microenvironments associated with different MET alterations in NSCLC, demonstrating immune-desert characteristics in MET-amplified tumors, while inflamed phenotypes were identified in cases of MET exon 14 skipping tumors.
Expert Insights on the Collaboration
Brandon Suh, CEO of Lunit, expressed enthusiasm regarding this partnership, stating, "Collaborating with Labcorp, recognized as a leader in diagnostics and clinical research, is a significant milestone in expanding the real-world application of AI in oncology. The initial studies indicate how AI can expose vital, predictive biomarkers found within pathology slides. This partnership is a testament to how digital pathology and AI can coalesce to enhance our understanding of precision oncology, bridging the gap between research and actual clinical care."
Similarly, Shakti Ramkissoon, M.D., Ph.D., MBA, Labcorp's vice president and medical lead for oncology, commented, "Our alliance with Lunit focuses on transforming complex pathology data into actionable insights. These studies illustrate how AI-enhanced digital pathology can identify patterns within tumors, ultimately aiding in treatment decisions, advancing biomarker development, and paving the way for personalized cancer therapies."
Future Directions in Oncology Research
Lunit and Labcorp have ambitious plans moving forward, aiming to extend their collaboration by applying AI-driven digital pathology techniques across various cancer types and exploring genomic correlations. This commitment not only marks a significant step forward in cancer research but also signifies both companies' dedication to enhancing patient care through advanced technological means.
About Lunit
Founded in 2013, Lunit (KRX: 328130) stands at the forefront in the fight against cancer, leveraging AI technology to revolutionize cancer care. Their clinically validated solutions encompass medical imaging, breast health, and biomarker analysis, aimed at facilitating earlier detection, optimizing treatment choices, and ensuring more precise patient outcomes across the cancer continuum.
Post the integration with Volpara, Lunit is equipped to offer a holistic suite from risk prediction and early detection to precision oncology. The FDA-cleared Lunit INSIGHT suite and innovative breast health solutions serve cancer screening at thousands of healthcare institutions worldwide, while the Lunit SCOPE platform is engaged in fruitful research partnerships with global pharmaceutical companies for biomarker development and companion diagnostics.
With trust established at over 10,000 sites spread across more than 65 countries, Lunit continues to merge deep medical expertise with an evolving data landscape to create substantial impacts for patients, clinicians, and researchers alike. Headquartered in Seoul, with a strong global presence, Lunit remains dedicated to forging ahead in the battle against cancer.
Frequently Asked Questions
What is the main objective of the collaboration between Lunit and Labcorp?
The partnership aims to innovate in digital pathology and artificial intelligence, focusing on oncology research and clinical applications.
How will the collaboration impact cancer diagnostics?
The collaboration seeks to utilize AI and digital pathology to enhance biomarker discovery and inform precision treatment strategies in cancer care.
What were the outcomes presented at SITC and AMP?
The studies showcased the identification of immune-active subtypes in tumors and revealed different tumor-immune microenvironments linked to MET alterations in NSCLC.
Who are the key leaders involved in this collaboration?
Brandon Suh, CEO of Lunit, and Shakti Ramkissoon, M.D., Ph.D., MBA, vice president at Labcorp, are the key figures driving this partnership.
What are the future plans for this collaboration?
Lunit and Labcorp plan to extend their collaboration to explore the applications of digital pathology AI across additional cancer types and their genomic correlations.
